News Image

BCLI: Initiation - Potential 10x Return on Successful Phase 3b. Promising Post Hoc and Biomarker Analysis Underpins Our NurOwn® Clinical Effectiveness Expectation

Provided By PR Newswire

Last update: Jun 14, 2024

FROM ACF EQUITY RESEARCH HEALTHCARE TEAM

NASDAQ: BCLI

READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE 

READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE

Read more at prnewswire.com

BRAINSTORM CELL THERAPEUTICS

NASDAQ:BCLI (4/22/2025, 4:56:48 PM)

0.8758

+0.02 (+1.84%)


Find more stocks in the Stock Screener

BCLI Latest News and Analysis

ChartMill News Image11 days ago - ChartmillOn Friday, there are stocks with unusual volume. Let's take a look.

Unusual volume stocks in Friday's session

Mentions: IPDN MBOT VERO NXPL ...

Follow ChartMill for more